Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Stock Has Consensus Price Target of $29.50

Shares of Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Get Free Report) have received an average recommendation of “Moderate Buy” from the seven analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $29.50.

Several research analysts have recently weighed in on the company. Wall Street Zen cut Adlai Nortye from a “buy” rating to a “hold” rating in a research report on Saturday, October 31st. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Adlai Nortye in a report on Tuesday, September 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Adlai Nortye in a research report on Monday, October 12th. Loop Capital set a $49.00 target price on Adlai Nortye in a report on Tuesday, September 8th. Finally, Jefferies Financial Group raised Adlai Nortye to a “strong-buy” rating in a research report on Monday, October 5th.

View Our Latest Research Report on ANL

Adlai Nortye Stock Down 5.6%

Shares of ANL opened at $8.55 on Thursday. Adlai Nortye has a 12-month low of $0.88 and a 12-month high of $17.25. The firm’s 50 day moving average is $12.43 and its 200-day moving average is $11.69.

Insider Transactions at Adlai Nortye

In related news, Director Ping Ji sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $15.99, for a total value of $159,900.00. Following the transaction, the director directly owned 121,453 shares of the company’s stock, valued at approximately $1,942,033.47. This trade represents a 7.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Xiaofeng Ye sold 5,667 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $14.25, for a total value of $80,754.75. Following the completion of the transaction, the chief financial officer directly owned 147,757 shares in the company, valued at approximately $2,105,537.25. This represents a 3.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 26,881 shares of company stock valued at $411,060 over the last ninety days.

Institutional Trading of Adlai Nortye

Several institutional investors have recently added to or reduced their stakes in ANL. Soleus Capital Management L.P. boosted its stake in Adlai Nortye by 213.8% during the third quarter. Soleus Capital Management L.P. now owns 1,272,355 shares of the company’s stock worth $20,358,000 after buying an additional 866,832 shares in the last quarter. Braidwell LP bought a new position in Adlai Nortye during the second quarter valued at $9,145,000. Boone Capital Management LLC bought a new position in shares of Adlai Nortye during the second quarter valued at about $2,971,000. Affinity Asset Advisors LLC purchased a new position in shares of Adlai Nortye during the first quarter valued at approximately $1,140,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Adlai Nortye during the 1st quarter worth $816,000. 35.21% of the stock is currently owned by hedge funds and other institutional investors.

About Adlai Nortye

(Get Free Report)

Adlai Nortye is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Founded in 2004 and headquartered in Hangzhou, China, the company conducts drug research and development for potential use in China and international markets. Its investigational oncology pipeline includes AN2025, a pan-RAF inhibitor; AN0025, an EP4 antagonist; and AN4005, an adenosine A2A/A2B receptor antagonist. These candidates are being studied for their potential to treat solid tumors, including in combination with other cancer therapies.

Recommended Stories

Analyst Recommendations for Adlai Nortye (NASDAQ:ANL)

Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.